International Small Molecule Treatment 
Drug Target Review
DECEMBER 13, 2024
2 Unmet needs in lung cancer treatment Recent decades have seen significant advancements in lung cancer treatment, especially with the introduction of targeted therapies and immunotherapies, which have notably improved survival rates. 18 Indeed, early-phase clinical studies exploring TsAbs in solid tumours have recently commenced.
PLOS: DNA Science
SEPTEMBER 5, 2024
Gleevec is a small molecule that interferes with entry of an enzyme – a tyrosine kinase – that enables growth signals to enter specific cells and trigger division. A name ending in “nib” means a small molecule that inhibits an enzyme called a kinase, and is short for “inhibit.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
NOVEMBER 6, 2023
Advances in research and development and the utilisation of combination treatment strategies are revolutionising the haematology care landscape, but more must be done to address patients’ individual needs. 2 It is this complexity that necessitates powerful, targeted combination therapies. References Blood Cancer UK.
Drug Target Review
AUGUST 25, 2023
What makes RRx-001 a first-in-class hypoxia-activated therapeutic, and how does its dual mechanism of action differ from traditional cancer treatments? Most, if not all, traditional cancer treatments are single minded. The name is a quasi-portmanteau of the chemical constituents of nibrozetone: ni tro, bro mine, and k etone.
The Pharma Data
NOVEMBER 19, 2020
Structure-based design approach has identified potent compounds for further development as oral treatments for SARS-CoV-2 infection and related human coronaviruses. Sosei Heptares has successfully designed three distinct series of compounds with attractive anti-viral drug-like properties and advanced the most promising molecules.
The Pharma Data
NOVEMBER 30, 2020
Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. In addition, we have advanced zavegepant, our intra-nasal CGRP receptor antagonist, successfully through its first pivotal trial, also for the acute treatment of migraine. TOKYO and CAMBRIDGE, England , Dec.
Drug Target Review
JULY 13, 2023
Drug discovery is a complex and vital field that continually seeks to identify new therapeutic targets and develop effective treatments. They found that although the targets themselves may not be easily druggable due to their disordered nature, their ability to condense can be modulated using small molecules.
Expert insights. Personalized for you.
98 
Let's personalize your content